금융 뉴스 허브

Cancer treatment already costs hundreds of thousands of dollars — and it’s about to get even worse

Someone who survived brain cancer in the 1990s explains how the Affordable Care Act could have helped.

3 Reasons to Sell ZBH and 1 Stock to Buy Instead

Over the past six months, Zimmer Biomet’s shares (currently trading at $85.45) have posted a disappointing 12.4% loss, well below the S&P 500’s 9.1% gain. This might have investors contemplating their ...

United Kingdom: Seasonal distortions question growth lead – TD Securities

TD Securities’ James Rossiter argues that recent UK GDP data may overstate underlying momentum due to problematic seasonal adjustment by the ONS.

Top Midday Stories: White House Refutes Iran Report of Interim Peace Deal; Zscaler Shares Plunge After Fiscal Q4 Revenue Guidance Misses Estimates

The Dow Jones Industrial Average was up, while the S&P 500 and Nasdaq Composite were about flat in l

Dow Jones Industrial Average leans on defensives while the AI trade wobbles

The Dow Jones Industrial Average (DJIA) is having its moment, holding a modest gain near 50,700 in the mid-session while the S&P 500 and Nasdaq Composite quietly leak red.

First fully AI-generated feature film to debut at Tribeca Film Festival

ISCV Beat IJJ Over the Past Year. Here's Why That Gap Could Easily Reverse.

Compare expense ratios, diversification, and risk profiles as these two value-focused ETFs take distinct approaches to portfolio construction.

Rocket One Rebrand Marks Strategic Shift Toward Space AI Chip and Orbital Computing Markets (RKTO)

Hoth Therapeutics is rebranding as Rocket One and pivoting toward space-focused AI chip infrastructure, targeting low-power, radiation-tolerant computing systems for orbital and defense applications. ...

CHAT vs. XLK: CHAT Outperforms XLK on Returns, But XLK Offers on Fees

One ETF delivers a higher dividend yield and sharper price swings, while the other boasts a massive asset base and broader sector coverage.

Hims & Hers rises after over $1M insider buy

52-week highs for Dycom, Vicor, Shoals, Luxfer on data growth, power demand

JBT Marel (JBTM): 3 Reasons We Love This Stock

Since November 2025, JBT Marel has been in a holding pattern, posting a small loss of 4% while floating around $134.91. The stock also fell short of the S&P 500’s 9.1% gain during that period.